Vibeke Strand

Active 1980–2025

189
Papers
31,671
Citations
96
h-index
182
i10-index

Citations

Citations per year for Vibeke Strand1974: 2 citations1982: 1 citations1983: 2 citations1984: 3 citations1985: 1 citations1986: 5 citations1987: 1 citations1990: 1 citations1992: 2 citations1994: 1 citations1995: 3 citations1996: 13 citations1997: 10 citations1998: 18 citations1999: 54 citations2000: 56 citations2001: 66 citations2002: 112 citations2003: 119 citations2004: 189 citations2005: 186 citations2006: 172 citations2007: 174 citations2008: 173 citations2009: 255 citations2010: 249 citations2011: 303 citations2012: 253 citations2013: 252 citations2014: 238 citations2015: 287 citations2016: 262 citations2017: 291 citations2018: 232 citations2019: 929 citations2020: 922 citations2021: 920 citations2022: 754 citations2023: 486 citations2024: 912 citations2025: 391 citations2026: 9 citations1975–1981: no citations, so these years are not shown1988–1989: no citations, so these years are not shown1991: no citations, so this year is not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,965 citing papers, 18.8% of this breakdownUnited Kingdom: 1,552 citing papers, 9.9% of this breakdownCanada: 961 citing papers, 6.1% of this breakdownGermany: 809 citing papers, 5.1% of this breakdownNetherlands: 806 citing papers, 5.1% of this breakdownChina: 775 citing papers, 4.9% of this breakdownItaly: 690 citing papers, 4.4% of this breakdownFrance: 642 citing papers, 4.1% of this breakdownAustralia: 568 citing papers, 3.6% of this breakdownSpain: 444 citing papers, 2.8% of this breakdownJapan: 411 citing papers, 2.6% of this breakdownSwitzerland: 389 citing papers, 2.5% of this breakdown
0%18.8%Other 30.1%

Fields

  • Medicine78.9%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Immunology and Microbiology6.3%
  • Social Sciences1.6%
  • Neuroscience1%
  • Health Professions0.9%
  • Other4%

Topics

  • Rheumatoid Arthritis Research and Therapies14.7%
  • Spondyloarthritis Studies and Treatments6.9%
  • Systemic Lupus Erythematosus Research5.3%
  • Autoimmune and Inflammatory Disorders Research4.6%
  • Osteoarthritis Treatment and Mechanisms3.7%
  • Psoriasis: Treatment and Pathogenesis2.9%
  • Other61.9%

Coauthors

All papers

Open in search
  1. Rheumatoid arthritis

    Authors: , , , , , , , , , , - Nature Reviews Disease Primers 2018 cited by 2,452

  2. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

    Authors: , , , , , , , , , - Arthritis & Rheumatology 2020 cited by 228

  3. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jasvinder A. Singh, Ilona Steigerwald, Vibeke Strand, Leslie Tive, Jeffrey Tobias, Ajay D. Wasan, Hilary Wilson - Pain 2020 cited by 181

  4. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theodore Pincus, Pamela Richards, Jeffrey N. Siegel, Lee S. Simon, Tuulikki Sokka, Vibeke Strand, Peter Tugwell, Alan Tyndall, Desirée van der Heijde, Suzanne Verstappen, Barbara White, Frederick Wolfe, A. Zink, Maarten Boers - Annals of the Rheumatic Diseases 2011 cited by 1,019

  5. OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

    Authors: , , , , , , , , , - Osteoarthritis and Cartilage 2004 cited by 854

  6. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

    Authors: , , - Seminars in Arthritis and Rheumatism 2021 cited by 143

  7. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , - Arthritis & Rheumatism 1995 cited by 2,844

  8. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Epidemiology 2014 cited by 784

  9. Sex- and gender-related differences in psoriatic arthritis

    Authors: , , , , , , - Nature Reviews Rheumatology 2022 cited by 94

  10. Novel evidence‐based systemic lupus erythematosus responder index

    Authors: , , , , , , , , , , , - Arthritis Care & Research 2009 cited by 485

  11. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

    Authors: , , , , , , , , , - BioDrugs 2017 cited by 351

  12. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2016 cited by 272

  13. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raphael Scarpa, Yeong Wook Song, Enrique R. Soriano, Paul P. Tak, Ilona Újfalussy, Kurt de Vlam, Jessica A. Walsh - Annals of the Rheumatic Diseases 2012 cited by 319

  14. Immunogenicity of biologic agents in rheumatology

    Authors: , , - Nature Reviews Rheumatology 2020 cited by 99

  15. It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10: Figure 1.

    Authors: , , , , , , - The Journal of Rheumatology 2011 cited by 158

  16. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology

    Authors: , , , , , , , , , , , , , , , - The Journal of Rheumatology 2019 cited by 100

  17. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis

    Authors: , , , , , , - The Lancet Rheumatology 2023 cited by 38

  18. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis

    Authors: , , , , , , , , , , , - Drug Safety 2016 cited by 147

  19. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies

    Authors: , , , , , , , , , , , , , , , - The Journal of Rheumatology 2019 cited by 144

  20. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019

    Authors: , , , , - Drug Safety 2021 cited by 88

  21. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

    Authors: , , , , , , , , , , - Annals of the Rheumatic Diseases 2013 cited by 338

  22. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop

    Authors: , , , , , , , , , , , , , , - The Journal of Rheumatology 2015 cited by 174

  23. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2023 cited by 35

  24. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jasvinder A. Singh, Shannon M. Smith, Vibeke Strand, Peter Tugwell, Gertrude F. Vanhove, Christin Veasley, Gary A. Walco, Ajay D. Wasan, James Witter - Pain 2016 cited by 211